All In Biotech

Drug Trial Radar · NCT05521438

Safety, Tolerability and Efficacy of QRX003 Lotion in Subjects With Netherton Syndrome

A Multicenter, Randomized, Vehicle-Controlled, Double-Blind, Parallel Comparison Study of QRX003 Lotion in Subjects With Netherton Syndrome

Last checked: Nov 19, 2026Latest source record: Mar 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

30

Planned (sponsor's estimate)

Start

Jun 23, 2022

Primary completion

Dec 30, 2025

Study completion Dec 31, 2026

Sponsor

Lead sponsor
Quoin PharmaceuticalsIndustry
Sponsor type
Industry
First posted
Aug 30, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 14 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study has been designed to determine the safety, tolerability and efficacy of QRX003 lotion 2%, 4% QAM or 4% BID in subjects with Netherton Syndrome (NS) in comparison to vehicle

Conditions

  • Netherton Syndrome

Interventions

  • QRX003-2% LotionDrug

    QRX003Topical Lotion containing 2% active drug (serine protease inhibitor)

  • QRX003-4% Lotion QAMDrug

    QRX003Topical Lotion containing 4% active drug (serine protease inhibitor)

  • VehicleDrug

    Vehicle Lotion

  • QRX003-4% Lotion BIDDrug

    QRX003Topical Lotion containing 4% active drug (serine protease inhibitor)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Efficacy Endpoints-1-point IGATime frame: Up to week 16
  2. Efficacy Endpoints-2-point IGATime frame: Up to week 16
  3. Efficacy Endpoints-NS SignTime frame: Up to week 16
  4. Efficacy Endpoints-BSATime frame: Up to week 16
  5. Efficacy Endpoints-WI-NRS scoreTime frame: Up to week 16
  6. Efficacy Endpoints-TSQMTime frame: Up to week 16
  7. Efficacy Endpoints-Rescue TherapyTime frame: Up to week 16
  8. Safety Endpoints-AEsTime frame: Up to week 16
  9. Safety Endpoints-LSRTime frame: Up to week 16

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • Site #1

    San Diego, California

  • Site #4

    Indianapolis, Indiana

  • Site #5

    Quincy, Massachusetts

  • Site #3

    Charleston, South Carolina

  • Site #2

    San Antonio, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.